Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives. | Drugs | 2026 | 42527846 | PubTator, text mining | PubMed |
| Immunotherapy and the novel therapeutic development for small-cell lung cancer. | Ther Adv Med Oncol | 2026 | 42523863 | PubTator, text mining | PubMed |
| Machine learning-driven identification of DLL3 as a molecular target and development of a DLL3-binding cyclic peptide for glioblastoma. | Front Oncol | 2026 | 42523549 | PubTator, text mining | PubMed |
| EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report. | JTO Clin Res Rep | 2026 | 42519408 | PubTator, text mining | PubMed |
| A case of Large Cell Neuroendocrine Carcinoma (LCNEC) treated with tarlatamab. | Int Cancer Conf J | 2026 | 42491047 | PubTator, text mining | PubMed |
| Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer. | Cancer Res | 2026 | 42489524 | PubTator, text mining | PubMed |
| Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report. | Front Oncol | 2026 | 42482749 | PubTator, text mining | PubMed |
| CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. | Mol Ther | 2026 | 42478044 | PubTator, text mining | PubMed |
| Multi-omics characterization of IDH-mutant astrocytoma-derived cell lines reveals NOTCH-regulated plastic quiescent astrocyte-like state and insights into progression. | Acta Neuropathol Commun | 2026 | 42477819 | PubTator, text mining | PubMed |
| The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer. | Pharmacol Res | 2026 | 42476348 | PubTator, text mining | PubMed |
| Analysis of SLFN11 expression in small cell lung cancer, carcinoids and large cell neuroendocrine carcinoma: insights into lung neuroendocrine neoplasms. | Lung Cancer | 2026 | 42470748 | PubTator, text mining | PubMed |
| Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms. | Cancers (Basel) | 2026 | 42449718 | PubTator, text mining | PubMed |
| Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem. | Cancers (Basel) | 2026 | 42449715 | PubTator, text mining | PubMed |
| Spatial mapping of Notch signaling components along the bull genital tract and in epididymal and vas deferens vesicles. | Anim Reprod Sci | 2026 | 42447766 | PubTator, text mining | PubMed |
| Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer. | Cancer Res | 2026 | 42423390 | PubTator, text mining | PubMed |
| Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms. | JCO Oncol Pract | 2026 | 42418753 | PubTator, text mining | PubMed |
| Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors. | Cancer Res Commun | 2026 | 42378456 | PubTator, text mining | PubMed |
| Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine. | Expert Rev Anticancer Ther | 2026 | 42376796 | PubTator, text mining | PubMed |
| Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians. | Ther Adv Med Oncol | 2026 | 42369724 | PubTator, text mining | PubMed |
| Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies. | Am Soc Clin Oncol Educ Book | 2026 | 42361287 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=3